Funded Biotechnology Startups in Basel
Basel's biotechnology cluster spans a wide capital range within these 23 recorded financings, from DropGen's $30K pre-seed in July 2025 to Noema Pharma's $…
Basel's biotechnology cluster spans a wide capital range within these 23 recorded financings, from DropGen's $30K pre-seed in July 2025 to Noema Pharma's $147M Series B in December 2024. Granite Bio's $70M Series B in April 2025 and Nouscom's $83M raise in March 2024 confirm that large-round activity has continued into the mid-2020s, while NXI Therapeutics' $4M pre-seed in June 2024 points to parallel early-stage formation in the same period.
The 2020–2022 cohort generated several of the set's largest tickets: VectivBio raised $125M via a post-IPO equity placement in October 2022, Bright Peak Therapeutics closed $107M in June 2021, and Monte Rosa Therapeutics completed a $95M Series C in March 2021. Stage labeling is inconsistent across the dataset — six entries carry no round type and five are tagged "Series Unknown" — a pattern common in Swiss private biotech markets where disclosure norms differ from US or UK equivalents.
Most recent rounds
23 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Basel biotech companies?
Noema Pharma's $147M Series B (December 2024) is the largest, followed by VectivBio's $125M post-IPO equity placement (October 2022) and Bright Peak Therapeutics' $107M round (June 2021). Monte Rosa Therapeutics ($95M Series C, March 2021) and Nouscom ($83M, March 2024) also clear $80M. Granite Bio's $70M Series B in April 2025 is the largest round with a disclosed stage from the past 12 months.
Which companies in this set raised in 2024 or 2025?
Six rounds are dated 2024 or later: DropGen (Pre-Seed, $30K, July 2025), Granite Bio (Series B, $70M, April 2025), Noema Pharma (Series B, $147M, December 2024), BioVersys (Series Unknown, $6M, September 2024), NXI Therapeutics (Pre-Seed, $4M, June 2024), and Nouscom ($83M, March 2024). Both 2025 entries represent opposite ends of the size spectrum — $30K and $70M.
Are any of the listed companies publicly traded?
Kinarus Therapeutics trades on SIX Swiss Exchange under the ticker KNRS and disclosed a $2M round in May 2023. VectivBio raised a $125M post-IPO equity round in October 2022, indicating it was publicly listed at that point.
How does round stage distribution break down across these 23 companies?
Five entries are tagged 'Series Unknown' (BioVersys, FimmCyte, Kinarus Therapeutics, Acthera Therapeutics, and TargImmune Therapeutics), and six carry no stage label at all (Nouscom, Bright Peak Therapeutics, T3 Pharmaceuticals, Versameb, Arvelle Therapeutics, FoRx Therapeutics). Named institutional stages — Pre-Seed (2), Seed (2), Series A (1), Series B (2), Series C (1), Post-IPO Equity (1) — account for nine companies. Debt financing and private equity structures cover three more.
What does the low end of the funding range look like?
DropGen's $30K pre-seed in July 2025 is the smallest disclosed amount in the set. FGen, MaxWell Biosystems, and ten23 health each recorded $100K rounds in late 2021, structured as debt financing or private equity. FimmCyte and Acthera Therapeutics list undisclosed amounts, so their actual size is unknown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.